ALLR News and Press, Allarity Therapeutics Inc. From 09/17/25

TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor...

2025-08-27 15:34:23 ET DENVER, Colo., Aug 27, 2025 ( 247marketnews.com )- It’s the final stretch of trading, and several small-cap biotechs are lighting up the tape with fresh catalysts. Allarity (NASDAQ:ALLR) is dominating today’s biotech headlines, surging over 1...

A look at the top 10 most actives in the United States Incannex Healthcare Inc. (IXHL) fell 4.1% to $0.7098 on volume of 490,264,150 shares Opendoor Technologies Inc (OPEN) rose 3.5% to $4.7 on volume of 481,123,076 shares Allarity Therapeutics Inc. (ALLR) rose 51.9% to $1.43 on volume of 3...

2025-08-26 14:38:13 ET DENVER, Colo., Aug 26, 2025 ( 247marketnews.com )- As markets head into the last trading hour, today’s movers span biotech breakthroughs, green energy plays, and emergent tech. Biotech Surge Allarity Therapeutics (NASDAQ:ALLR) Fast-tracked...

A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 122.0% to $2.0894 on volume of 156,874,466 shares Incannex Healthcare Inc. (IXHL) rose 13.8% to $0.8429 on volume of 120,020,692 shares Invivyd Inc. (IVVD) rose 52.8% to $0.8551 on volume of 86,034...

2025-08-26 09:42:44 ET DENVER, Colo., Aug 26, 2025 ( 247marketnews.com )- Biotechs are lighting up the tape. Allarity Therapeutics (NASDAQ:ALLR) is charging ahead after announcing FDA Fast Track designation for its dual PARP/WNT inhibitor stenoparib in advanced ovarian cancer. T...

TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—t...

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP ® companion diagnostic - Secured new service contract with EU biotech for Allarity Medical ...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

2025-08-10 18:45:14 ET Allarity Therapeutics, Inc. (ALLR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 10.19%. The average open to low on the day of earnings was -5.25%. The average o...